Search Results

Displaying Results 26-49 of 49 "'JG'"
Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.
OceanaGold Provides Notice of Fourth Quarter and Full Year 2025 Results and Conference Call

Jan 20, 2026, 17:00 ET OceanaGold Provides Notice of Fourth Quarter and Full Year 2025 Results and Conference Call

https://app.webinar.net/jg9VnRpdZO4Toll-free North America: 1-888-510-2154International: 1-437-900-0527If you are unable to attend the call, a recording

More news about: OceanaGold Corporation

Jan 06, 2026, 20:46 ET She Said Yes Unveils Its Holiday Jewelry Gift Guide, Making Meaningful Gifting Effortless This Season

https://shesaidyes.cc/91jg8This holiday season, She Said Yes invites shoppers to celebrate connection, joy, and generosity—using sparkling jewelry to convey

More news about: She Said Yes

Jan 06, 2026, 20:31 ET She Said Yes Partners with WeForest to Launch 1:1 Tree-Planting Initiative, Turning Every Jewelry Purchase into Climate Action

https://shesaidyes.cc/91jg8About She Said YesFounded on the belief that love deserves brilliance without compromise, She Said Yes has become

More news about: She Said Yes

Dec 16, 2025, 08:00 ET Reject Mining, Embrace Rebirth: She Said Yes Sets a New Standard for Sustainable Fine Jewelry with Lab-Grown Diamonds & Gemstones

https://shesaidyes.cc/91jg8About She Said YesShe Said Yes is a modern fine jewelry brand redefining luxury through laboratory-grown diamonds and

More news about: She Said Yes

Dec 16, 2025, 08:00 ET Moissanite Revolution: She Said Yes Reimagines Diamond Brilliance Through Technology, Art, and Zero-Conflict Luxury

https://shesaidyes.cc/91jg8About She Said YesFounded on the belief that love deserves brilliance without compromise, She Said Yes has become a

More news about: She Said Yes

Everflow Drives $4.3 Billion in High-Value Partner Revenue, Delivering Essential Solutions for Modern Affiliate Programs

Dec 11, 2025, 07:00 ET Everflow Drives $4.3 Billion in High-Value Partner Revenue, Delivering Essential Solutions for Modern Affiliate Programs

served as mission-critical marketing infrastructure for some of the world's most successful affiliate programs in 2025, including industry leaders like JG Wentworth, Moen, and Mutual of Omaha. The modern platform tracked billions of clicks and conversion events, while maintaining an industry-leading 99.99%

More news about: Everflow

Nov 24, 2025, 07:30 ET 2025 Annual General Meeting

Join the meeting hereTeams Meeting ID: 416 460 253 829 2 Passcode: jG7zH2p6Webcast participants will have the option to submit written questions during the meeting in relation to each resolution (as detailed in the

More news about: Hot Chili Limited

Operation Smile Launches "We Build Hope," Reframing Surgical Scars as Symbols of Strength, Survival and Access

Nov 19, 2025, 09:00 ET Operation Smile Launches "We Build Hope," Reframing Surgical Scars as Symbols of Strength, Survival and Access

The Lancet Commissions Global Surgery 2030: evidence and solutions for achieving health, welfare, and economic development by Meara JG, Leather AJ, Hagander L, Alkire BC, Alonso N, Ameh EA, et al 

More news about: Operation Smile

New long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis

Nov 17, 2025, 08:05 ET New long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis

4 Atreya R, Abreu MT, Krueger JG, et al. Guselkumab, an IL-23p19 subunit-specific monoclonal antibody, binds CD64+ myeloid cells and potentially neutralizes IL-23 produced from the same

More news about: Johnson & Johnson

Nov 16, 2025, 19:20 ET She Said Yes Introduces "15% Cost, 100% Certainty" -- Its High-Value Philosophy for Try-On Replicas

https://shesaidyes.cc/91jg4 About She Said Yes She Said Yes redefines how modern

More news about: She Said Yes

From "Virtual Imagination" to "Real Touch" -- She Said Yes Uses Tactile Marketing to Break the Dimensional Wall of Online Jewelry Shopping

Nov 13, 2025, 16:14 ET From "Virtual Imagination" to "Real Touch" -- She Said Yes Uses Tactile Marketing to Break the Dimensional Wall of Online Jewelry Shopping

https://shesaidyes.cc/91jg4 About She Said Yes She Said Yes

More news about: She Said Yes

Nov 11, 2025, 16:33 ET 'Tis the Season to Deck the Palms at The Ocean Club, A Four Seasons Resort, Bahamas

Year's Eve 5 course dinner is USD 295 per person. Amuse Bouche: Petrossian Caviar JG select, Smoked Egg Yolk, Crispy Potato cake First Course: Seared

More news about: The Ocean Club, A Four Seasons Resort, Bahamas

SupportPay Introduces Modern Family Finances to Strengthen Family Financial Harmony

Nov 05, 2025, 08:05 ET SupportPay Introduces Modern Family Finances to Strengthen Family Financial Harmony

according to JG Wentworth. SupportPay is pioneering this new category with a platform used by families of all structures, from siblings caring for aging parents

More news about: SupportPay

Everflow Fuels Inflektion's AI Personalization Engine to Help Customers Deliver More Conversions and Automation at Scale

Nov 05, 2025, 07:00 ET Everflow Fuels Inflektion's AI Personalization Engine to Help Customers Deliver More Conversions and Automation at Scale

marketing, discover new affiliates for growth, and identify your highest ROI traffic sources. Join 1,200+ brands at the forefront of growth, including JG Wentworth, Moen, and Golden Hippo. Learn more at

More news about: Everflow

TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years

Oct 27, 2025, 07:30 ET TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years

Atreya R, Abreu MT, Krueger JG, et al. Guselkumab, an IL-23p19 subunit-specific monoclonal antibody, binds CD64+ myeloid cells and potentially neutralizes IL-23 produced from the same

More news about: Johnson & Johnson

BIMZELX® (bimekizumab-bkzx) Three-Year Rheumatology Data at ACR 2025 Demonstrated Sustained Inflammation Control in Psoriatic Arthritis and Axial Spondyloarthritis

Oct 25, 2025, 11:00 ET BIMZELX® (bimekizumab-bkzx) Three-Year Rheumatology Data at ACR 2025 Demonstrated Sustained Inflammation Control in Psoriatic Arthritis and Axial Spondyloarthritis

IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis. 2018;77:523–32. Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate-to-severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised

More news about: UCB

TREMFYA® (guselkumab) is first and only IL-23 inhibitor to demonstrate sustained clinical and endoscopic outcomes with a fully subcutaneous regimen through 48 weeks in ulcerative colitis

Oct 07, 2025, 08:05 ET TREMFYA® (guselkumab) is first and only IL-23 inhibitor to demonstrate sustained clinical and endoscopic outcomes with a fully subcutaneous regimen through 48 weeks in ulcerative colitis

ASTRO study. Oral presentation OP203 at United European Gastroenterology (UEG) Week 2025. October 2025.2 Atreya R, Abreu MT, Krueger JG, et al. Guselkumab, an IL-23p19 subunit-specific monoclonal antibody, binds CD64+ myeloid cells and potentially neutralizes IL-23 produced from the same

More news about: Johnson & Johnson

Evofem's SOLOSEC Submitted for Marketing Approval in United Arab Emirates

Oct 01, 2025, 08:47 ET Evofem's SOLOSEC Submitted for Marketing Approval in United Arab Emirates

doi: 10.1097/OLQ.0000000000000972. PMID: 30624309. Harfouche M, Gherbi WS, Alareeki A, Alaama AS, Hermez JG, Smolak A, Abu-Raddad LJ. Epidemiology of Trichomonas vaginalis infection in the Middle East and North Africa: systematic review, meta-analyses, and meta-regressions.

More news about: Evofem Biosciences, Inc.

U.S. FDA approves TREMFYA® (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor

Sep 29, 2025, 08:00 ET U.S. FDA approves TREMFYA® (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor

Placebo-Controlled Study. Poster presented at: AAD Annual Meeting; March 7-11, 2025; Orlando, Florida.7 Atreya R, Abreu MT, Krueger JG, et al. Guselkumab, an IL-23p19 subunit-specific monoclonal antibody, binds CD64+ myeloid cells and potentially neutralizes IL-23 produced from the same

More news about: Johnson & Johnson

Arthrex Achieves First Case with NanoNeedle™ Scope 2.0

Sep 23, 2025, 10:36 ET Arthrex Achieves First Case with NanoNeedle™ Scope 2.0

ankle is safe and effective. Knee Surg Sports Traumatol Arthrosc. 2020;28(10):3080-3086. doi:10.1007/s00167-020-05889-7Schaver AL, Lash JG, MacAskill ML, et al. Partial meniscectomy using needle arthroscopy associated with significantly less pain and improved patient reported outcomes at

More news about: Arthrex, Inc.

TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen

Sep 19, 2025, 17:28 ET TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen

https://www.crohnscolitisfoundation.org/what-is-crohns-disease/overview. Accessed September 2025. 2 Atreya R, Abreu MT, Krueger JG, et al. Guselkumab, an IL-23p19 subunit-specific monoclonal antibody, binds CD64+ myeloid cells and potentially neutralizes IL-23 produced from the same

More news about: Johnson & Johnson

BIMZELX® (bimekizumab-bkzx) Data in Moderate-to-Severe Plaque Psoriasis at EADV Showed Complete Skin Clearance Sustained Over Four Years

Sep 17, 2025, 07:00 ET BIMZELX® (bimekizumab-bkzx) Data in Moderate-to-Severe Plaque Psoriasis at EADV Showed Complete Skin Clearance Sustained Over Four Years

trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis. 2018;77:523–32.17. Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate-to-severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised

More news about: UCB

BIMZELX® (bimekizumab-bkzx) New Three-year Data in Hidradenitis Suppurativa at EADV Showed Sustained Symptom Relief Across Multiple Clinical Endpoints

Sep 17, 2025, 07:00 ET BIMZELX® (bimekizumab-bkzx) New Three-year Data in Hidradenitis Suppurativa at EADV Showed Sustained Symptom Relief Across Multiple Clinical Endpoints

clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis. 2018;77:523–32.Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate-to-severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised

More news about: UCB

Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.